Kantum Pharma was founded based on pioneering work from the laboratory of our scientific founder, Dr. Sylvie Breton, at MGH/Harvard Medical School. The Company is focused on translating her important research on the UDP-glucose/P2Y14 receptor signaling pathway into potentially transformative therapies in order to improve outcomes and patients' lives. The company's lead program, KB-1801, is based on technology licensed from MGH and is currently in preclinical development for prevention of acute kidney injury. The company is pursuing additional applications of the technology for therapeutics and diagnostics associated with delayed graft function disorder, cystic fibrosis and inflammatory disorders of the female reproductive tract. Kantum's largest investor is Broadview Ventures. Chronic lung inflammation is a primary driver of pulmonary function decline in cystic fibrosis patients.
| Website | http://www.kantumpharma.com |
| Revenue | $1 million |
| Employees | View employees |
| Address | 75 S Main St Ste 7-160, Concord, New Hampshire 03301, US |
| Phone | +1 603-876-6200 |
| Industry | Manufacturing General, Manufacturing |
| Competitors | Novartis, Pfizer, Merck & Co., Inc., Roche, Bristol Myers Squibb, AstraZeneca, Sanofi, Gilead Sciences, Amgen, AbbVie +40 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies |
Looking for a particular Kantum Pharma employee's phone or email?
Kantum Pharma Questions
The Kantum Pharma annual revenue was $1 million in 2026.
Kantum Pharma is based in Concord, New Hampshire.
The NAICS codes for Kantum Pharma are [32, 3254, 325, 32541].
The SIC codes for Kantum Pharma are [28, 283].
